Pembrolizumab plus cisplatin and fluorouracil as induction chemotherapy followed by definitive chemoradiotherapy for patients with cT4 and/or supraclavicular lymph node metastasis (M1Lym) of esophageal squamous cell carcinoma.

MLA

Hokamura, Nobukazu, et al. “Pembrolizumab plus Cisplatin and Fluorouracil as Induction Chemotherapy Followed by Definitive Chemoradiotherapy for Patients with CT4 and/or Supraclavicular Lymph Node Metastasis (M1Lym) of Esophageal Squamous Cell Carcinoma.” Surgery Today, vol. 54, no. 11, Nov. 2024, pp. 1410–13. EBSCOhost, https://doi.org/10.1007/s00595-024-02867-1.

APA

Hokamura, N., Fukagawa, T., Fukushima, R., Kiyokawa, T., Horikawa, M., Kumata, Y., Suzuki, Y., & Midorikawa, H. (2024). Pembrolizumab plus cisplatin and fluorouracil as induction chemotherapy followed by definitive chemoradiotherapy for patients with cT4 and/or supraclavicular lymph node metastasis (M1Lym) of esophageal squamous cell carcinoma. Surgery Today, 54(11), 1410–1413. https://doi.org/10.1007/s00595-024-02867-1

Chicago

Hokamura, Nobukazu, Takeo Fukagawa, Ryoji Fukushima, Takashi Kiyokawa, Masahiro Horikawa, Yoshimasa Kumata, Yusuke Suzuki, and Hironori Midorikawa. 2024. “Pembrolizumab plus Cisplatin and Fluorouracil as Induction Chemotherapy Followed by Definitive Chemoradiotherapy for Patients with CT4 and/or Supraclavicular Lymph Node Metastasis (M1Lym) of Esophageal Squamous Cell Carcinoma.” Surgery Today 54 (11): 1410–13. doi:10.1007/s00595-024-02867-1.